Pathobiology Of Uterine Leiomyomas (fibroids)

子宫平滑肌瘤(肌瘤)的病理学

基本信息

项目摘要

The Molecular Pathogenesis Group has focused much of its research on defining the pathogenesis of disorders affecting the reproductive tract of humans and rodents and assessing the role of environmental and endogenous hormones, and growth factors on the growth and induction of these disorders. In understating the role of proliferation in human uterine leiomyoma (fibroid) growth, we have found that both positive and negative regulators of apoptosis are not differentially expressed in fibroids compared to normal myometria, and that altered apoptosis does not appear to play a significant role in the expansion of these tumors. Our studies show that cell proliferation and extracellular matrix production may be the most significant contributors to fibroid expansion, although, mitotic activity of fibroid cells appears to be phasic, does not correlate with tumor size, and is autonomous for each tumor within a uterus. In studies addressing the role of growth factors in the pathogenesis of fibroids, we have found that Receptor Tyrosine Kinases (RTKs) and their ligands are overexpressed in fibroids compared to normal myometria during the proliferative phase of the menstrual cycle and that many of the RTKs are activated. These studies will help to define some of the basic biological and molecular pathways important in fibroid growth, which can then be applied to developing alternative noninvasive treatment regimens for fibroids. We have also found that nonclassical estrogen receptors (ER), such as ERalpha36 and G protein-coupled ER (GPER) are important in fibroid cell growth and are responsive to environmental estrogen mimics. In vitro model systems for studying fibroids are limited in that human derived leiomyoma cells grow poorly in culture. We have overcome this obstacle by development of hTERT (human telomerase) immortalized uterine leiomyoma and myometrial cell lines. We have also developed 3D culture models of fibroid and myometrial cells to further mimic the in vivo microenvironment. These cells and 3D cultures are being used to study leiomyoma tumorigenesis in a prospective manner and to determine the impact of environmental exposures on fibroid cell growth and fibrosis. In determining the role of environmental agents in fibroid development and growth we have found that the phytoestrogen, genistein, can be stimulatory or inhibitory to uterine leiomyoma cell growth depending on its concentration. We have also found that Bisphenol A (BPA), can induce cell proliferation in uterine leiomyoma through a membrane-associated ER, ERalpha36, and may be potential risk factor for fibroids. Metals, such as Cadmium potentiate growth of human fibroid cells and continuous exposure results in genomic and morphologic alterations that drive the benign fibroid tumor cell towards a cancer phenotype.
分子发病机组的大部分研究集中在定义影响人类和啮齿动物生殖道的疾病的发病机理上,并评估环境和内源激素的作用,以及生长因子对这些疾病的生长和诱导的作用。在低估了增殖在人子宫平滑肌瘤(肌瘤)生长中的作用时,我们发现与正常肌分立相比,凋亡的阳性和阴性调节剂在肌瘤中均未差异表达,并且凋亡的改变似乎在这些肿瘤扩张中没有重要作用。我们的研究表明,细胞增殖和细胞外基质产生可能是肌瘤膨胀的最重要因素,尽管肌瘤细胞的有丝分裂活性似乎是阶段性的,与肿瘤的大小无关,并且对于子宫内的每个肿瘤都是自主的。在解决生长因子在肌瘤发病机理中的作用的研究中,我们发现受体酪氨酸激酶(RTK)及其配体在男性循环的增殖阶段与正常肌谱相比,在肌瘤中过表达肌瘤,并且许多RTK被激活。 这些研究将有助于定义一些在肌瘤生长中重要的基本生物学和分子途径,然后将其应用于开发肌瘤的替代性非侵入性治疗方案。我们还发现,非经典雌激素受体(ER),例如Eralpha36和G蛋白偶联ER(GPER)在肌瘤细胞的生长中很重要,并且对环境雌激素模拟物有反应。用于研究肌瘤的体外模型系统受到限制,因为人类衍生的平滑肌瘤细胞在培养中生长较差。我们通过发展HTERT(人端粒酶)永生的子宫平滑肌瘤和肌层细胞系来克服这一障碍。我们还开发了肌瘤和肌层细胞的3D培养模型,以进一步模拟体内微环境。这些细胞和3D培养物用于前瞻性研究平滑肌瘤肿瘤发生,并确定环境暴露对肌瘤细胞生长和纤维化的影响。在确定环境药物在肌瘤发育和生长中的作用时,我们发现植物雌激素,染料黄酮可以刺激性或抑制性子宫平滑肌瘤细胞的生长,具体取决于其浓度。我们还发现,双酚A(BPA)可以通过膜相关的ER,ERALPHA36诱导子宫平滑肌瘤的细胞增殖,并且可能是肌瘤的潜在危险因素。金属,例如镉增强人肌瘤细胞的生长和连续暴露会导致基因组和形态学改变,从而将良性肌瘤细胞推向癌症表型。

项目成果

期刊论文数量(50)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
NTP/NIEHS Global Contributions to Toxicologic Pathology.
NTP/NIEHS 对毒理学病理学的全球贡献。
  • DOI:
    10.1177/0192623317740326
  • 发表时间:
    2017
  • 期刊:
  • 影响因子:
    1.5
  • 作者:
    Sills,Robert;Brix,Amy;Cesta,Mark;Churchill,ShebaR;Cora,MichelleC;Dixon,Darlene;Dykstra,Michael;Flake,Gordon;Herbert,Ron;Kovi,Ramesh;Janardhan,Kyathanahalli;King-Herbert,Angela;Malarkey,David;Pandiri,Arun;Travlos,Greg;Willso
  • 通讯作者:
    Willso
Recommendations from the INHAND Apoptosis/Necrosis Working Group.
  • DOI:
    10.1177/0192623315625859
  • 发表时间:
    2016-02
  • 期刊:
  • 影响因子:
    1.5
  • 作者:
    Elmore SA;Dixon D;Hailey JR;Harada T;Herbert RA;Maronpot RR;Nolte T;Rehg JE;Rittinghausen S;Rosol TJ;Satoh H;Vidal JD;Willard-Mack CL;Creasy DM
  • 通讯作者:
    Creasy DM
An endocrine-disrupting chemical, fenvalerate, induces cell cycle progression and collagen type I expression in human uterine leiomyoma and myometrial cells.
  • DOI:
    10.1016/j.toxlet.2010.03.004
  • 发表时间:
    2010-07-15
  • 期刊:
  • 影响因子:
    3.5
  • 作者:
    Gao, Xiaohua;Yu, Linda;Castro, Lysandra;Moore, Alicia B.;Hermon, Tonia;Bortner, Carl;Sifre, Maria;Dixon, Darlene
  • 通讯作者:
    Dixon, Darlene
Epigenetic Enzymes, Age, and Ancestry Regulate the Efficiency of Human iPSC Reprogramming.
  • DOI:
    10.1002/stem.2899
  • 发表时间:
    2018-11
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Mackey LC;Annab LA;Yang J;Rao B;Kissling GE;Schurman SH;Dixon D;Archer TK
  • 通讯作者:
    Archer TK
Glucocorticoids regulate gene expression and repress cellular proliferation in human uterine leiomyoma cells.
  • DOI:
    10.1007/s12672-012-0103-0
  • 发表时间:
    2012-06
  • 期刊:
  • 影响因子:
    3
  • 作者:
    Whirledge S;Dixon D;Cidlowski JA
  • 通讯作者:
    Cidlowski JA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DARLENE DIXON其他文献

DARLENE DIXON的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DARLENE DIXON', 18)}}的其他基金

Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    6837386
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    7006518
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    7161818
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    9550002
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    9787038
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
PATHOBIOLOGY OF UTERINE LEIOMYOMAS (FIBROIDS)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    6289903
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    6542231
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    8929703
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    8734051
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:
Pathobiology Of Uterine Leiomyomas (fibroids)
子宫平滑肌瘤(肌瘤)的病理学
  • 批准号:
    7327249
  • 财政年份:
  • 资助金额:
    $ 110.58万
  • 项目类别:

相似国自然基金

草鱼贮藏过程肌细胞凋亡对鱼肉品质的影响机制研究
  • 批准号:
    32372397
  • 批准年份:
    2023
  • 资助金额:
    50 万元
  • 项目类别:
    面上项目
VNN1通过内质网非折叠蛋白应激介导单核巨噬细胞凋亡影响创伤患者脓毒症发生的机制研究
  • 批准号:
    82372549
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
MLCK1介导细胞凋亡和自噬影响炎症性肠病进展
  • 批准号:
    82370568
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
EHMT1通过CBX4/MLKL轴调控心肌细胞坏死性凋亡影响心肌缺血再灌注损伤的机制研究
  • 批准号:
    82370288
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
应激颗粒自噬对低氧诱导猪卵泡颗粒细胞凋亡的影响及机制研究
  • 批准号:
    32302741
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

A HUMAN IPSC-BASED ORGANOID PLATFORM FOR STUDYING MATERNAL HYPERGLYCEMIA-INDUCED CONGENITAL HEART DEFECTS
基于人体 IPSC 的类器官平台,用于研究母亲高血糖引起的先天性心脏缺陷
  • 批准号:
    10752276
  • 财政年份:
    2024
  • 资助金额:
    $ 110.58万
  • 项目类别:
The Role of Glycosyl Ceramides in Heart Failure and Recovery
糖基神经酰胺在心力衰竭和恢复中的作用
  • 批准号:
    10644874
  • 财政年份:
    2023
  • 资助金额:
    $ 110.58万
  • 项目类别:
Catheter-injectable system for local drug delivery after myocardial infarct
用于心肌梗死后局部给药的导管注射系统
  • 批准号:
    10722614
  • 财政年份:
    2023
  • 资助金额:
    $ 110.58万
  • 项目类别:
Translational Multimodal Strategy for Peri-Implant Disease Prevention
种植体周围疾病预防的转化多模式策略
  • 批准号:
    10736860
  • 财政年份:
    2023
  • 资助金额:
    $ 110.58万
  • 项目类别:
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
特发性肺纤维化新型治疗剂的临床前开发
  • 批准号:
    10696538
  • 财政年份:
    2023
  • 资助金额:
    $ 110.58万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了